Physician profile
Isoken Koko
NPI 1265465728
$16,647.43
in general payments reported to CMS, 2019-2025
50 companies · $1,574 in 2025
The $1,574 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,029 · 2020: $1,810 · 2021: $668 · 2022: $2,283 · 2023: $1,114 · 2024: $2,169 · 2025: $1,574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,336 · Education: $521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,335.86 |
| Education | $521.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $5,429.94 | 2019-2025 | Rybrevant, Carvykti, Imbruvica |
| Seagen INC. | $1,573.99 | 2022-2025 | |
| Pfizer INC. | $1,107.73 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $964.45 | 2020-2023 | |
| Genentech USA, INC. | $785.99 | 2019-2024 | Tecentriq, Kadcyla, Phesgo |
| Merck Sharp & Dohme LLC | $648.75 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $642.32 | 2019-2025 | Piqray, Kisqali |
| E.R. Squibb & Sons, L.L.C. | $542.63 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Gilead Sciences, INC. | $517.55 | 2021-2025 | Trodelvy |
| Astellas Pharma US INC | $433.27 | 2019-2025 | Xtandi, Padcev |
| Incyte Corporation | $405.16 | 2019-2024 | Monjuvi |
| Astrazeneca Pharmaceuticals LP | $377.84 | 2019-2025 | Lynparza, Calquence, Imfinzi |
| Abbvie INC. | $376.14 | 2023-2025 | |
| Celgene Corporation | $291.73 | 2019-2025 | Reblozyl, Pomalyst |
| Daiichi Sankyo INC. | $287.84 | 2023-2025 | Enhertu, Datroway, Vanflyta |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isoken Koko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.